Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.German drug company Altana has filed applications in the US and Canada seeking marketing approval for a ciclesonide nasal spray for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, a condition commonly referred to as hey fever.
Subscribe to our email newsletter
Besides the nasal spray, ciclesonide is the active substance of an inhaled corticosteroid that is already approved in 35 countries worldwide for the treatment of persistent asthma.
In addition, the ciclesonide platform will also include a fixed combination product with a long-acting beta-agonist, currently in phase II of clinical development.
Intranasal corticosteroids are considered to be the gold standard for the treatment of allergic rhinitis, and they work by reducing inflammation, which is the major underlying cause of nasal symptoms.
“The submissions of ciclesonide nasal spray represent a major milestone for us, as they reinforce our commitment to providing innovative treatments for respiratory diseases,” said Dr Hans-Joachim Lohrisch, CEO of Altana Pharma.
Altana partners with Sanofi-Aventis in the US and with Teijin in Japan on various ciclesonide based products.